Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
849.6 INR | -0.52% | +0.81% | +29.30% |
11/07 | Glenmark Pharmaceuticals to Sell 7.84% Stake in Glenmark Life Sciences | MT |
10/07 | Glenmark Pharma to Sell 7.84% Stake in Glenmark Life via Offer for Sale | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's enterprise value to sales, at 4.24 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+29.30% | 125.34Cr | D | ||
+55.35% | 82TCr | C+ | ||
+32.47% | 60TCr | B | ||
-0.10% | 38TCr | C+ | ||
+15.47% | 32TCr | B- | ||
+13.10% | 31TCr | C+ | ||
+16.49% | 25TCr | B+ | ||
+14.55% | 23TCr | B- | ||
+16.54% | 18TCr | C+ | ||
+4.31% | 17TCr | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GLS Stock
- GLS Stock
- Ratings Glenmark Life Sciences Limited